Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology
Key facts
- Where
- Webster, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Profil USWebster, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Profil Institut für Stoffwechselforschung GmbH
- Trial code
- NCT07913698
- Record updated
- 3 November 2026
- Original description
This trial will establish fully-automated glucose clamping using state-of-the-art technology (ClampArt®) at a US based clinical research centerRead full original descriptionShow less
This trial will establish fully-automated glucose clamping using state-of-the-art technology (ClampArt®) at a US based clinical research center
Inclusion: Signed and dated informed consent has been obtained; Participant is male or female; Age between 18 and 65 years, both inclusive; Obese people or people diagnosed with type 2 diabetes; BMI, > 30 kg/m2, for obese participants and people with type 2 diabetes; Has venous access sufficient to allow cannulation for blood sampling as required by the protocol.
Exclusion: Previous participation in this trial. Participation is defined as having completed at least one clamp; A positive result in the alcohol and/or urine drug screen at the screening visit; Current use of systemic medication that could interfere with the interpretation of the trial endpoints (insulin sensitivity assessment), as judged by the Investigator; History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction; Any serious systemic infectious disease within the last four weeks, as judged by the investigator; Signs of acute illness as judged by the investigator; Significant history of alcoholism as judged by the investigator or consuming more than 24.0 grams alcohol/day (for males), 12.0 grams alcohol/day (for females) on average; Tested positive for hepatitis Bs antigen; Tested positive for hepatitis C antibodies. (Presence of hepatitis C antibodies will not lead to exclusion if liver function tests are normal and a hepatitis C polymerase chain reaction is negative); Positive result to the test for HIV-1/2 antibodies or HIV-1 antigen; Clinically significant abnormal screening laboratory tests, as judged by the investigator; Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial; Clinically relevant comorbidity, capable of constituting a risk for the participant when participating in the trial or of interfering with the interpretation of data; Clinically significant abnormal findings for vital signs and ECG recordings, as judged by the investigator; Daily smoker or using nicotine substitute products; Blood donation or blood loss of more than 500 mL within the last 3 months; If female, pregnancy or breast-feeding.